Antithrombin deficiencies are mainly divided into two types: type I and type II. The type I antithrombin deficiency is characterized by an inadequate amount of normal antithrombin present in the bloodstream.
New York, NY -- (SBWIRE) -- 12/06/2016 -- The global antithrombin III deficiency testing market is categorized on the basis of various types of deficiencies, diagnostic procedures, and end users. Based on the type of deficiencies, the report covers type I antithrombin deficiency and type II antithrombin deficiency. Based on the type of technology, the report covers monoclonal antibodies, molecular diagnostics, differential light scattering, immunoassays, flow cytometry, chromatography, gel micro droplets, diagnostic imaging, and others. Based on end users, the report covers commercial or private labs, physician offices, hospitals, public health labs, and academic research institutes.
In terms of geography, North America dominates the global antithrombin III deficiency testing market. This is due to increased government funding on healthcare infrastructure in the region. In addition, technological advancement in antithrombin III diagnostic procedures has also propelled the market in North America. The U.S. represents the largest market for antithrombin deficiency testing in North America, followed by Canada. In Europe, Germany, France, and the U.K. hold the major shares of the antithrombin III deficiency testing market. The antithrombin III deficiency testing market in Asia is also expected to show high growth rates in the next five years. This is due to the various initiatives undertaken by governments to increase awareness about blood clotting disorders in the region. In addition, increased investments by many foreign diagnostic instrument companies have also propelled the growth of the antithrombin III deficiency testing market in the region. India, China, and Japan are expected to be the fastest-growing markets for antithrombin III deficiency testing in Asia.
Advanced applications of antithrombin deficiency diagnostic instruments and increasing prevalence of blood clot disorders are the key drivers for the global antithrombin III deficiency testing market. Also, increased government support in the form of funding and rapid technological advancements have fueled the growth of this market.
An increasing number of mergers and acquisitions involving diagnostic consumables manufacturing companies and rapid product launches are the key trends in the global antithrombin III deficiency testing market.
Request for Sample Report and Table of content @ http://www.persistencemarketresearch.com/samples/4272
The major companies operating in this market are Abbott Laboratories, Avocet Medical Inc., Axis-Shield plc, Beckman Coulter Inc., Becton, Dickinson and Company, Trinity Biotech PLC, Thermo Fisher Scientific, Inc., Siemens AG, Roche, Chrono-log Corporation, Sysmex Corporation, Hyphen Biomed and American Diagnostica GmbH.